{
    "id": 3111,
    "fullName": "EGFR A750P",
    "impact": "missense",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "EGFR A750P lies within the protein kinase domain of the Egfr protein (UniProt.org). A750P results in ligand-independent phosphorylation of Egfr in cell culture and promotes tumor formation in xenograft models in one study (PMID: 19625781), but induces similar cell proliferation and cell viability as wild-type Egfr in two different cell lines in another study (PMID: 29533785), and therefore, its effect on Egfr protein function is unknown.",
            "references": [
                {
                    "id": 295,
                    "pubMedId": null,
                    "title": null,
                    "url": "https://www.uniprot.org"
                },
                {
                    "id": 1889,
                    "pubMedId": 19625781,
                    "title": "BB, a new EGFR inhibitor, exhibits prominent anti-angiogenesis and antitumor activities.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/19625781"
                },
                {
                    "id": 11238,
                    "pubMedId": 29533785,
                    "title": "Systematic Functional Annotation of Somatic Mutations in Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29533785"
                }
            ]
        }
    ],
    "type": null,
    "gene": {
        "id": 1956,
        "geneSymbol": "EGFR",
        "terms": [
            "EGFR",
            "ERBB",
            "ERBB1",
            "HER1",
            "mENA",
            "NISBD2",
            "PIG61"
        ]
    },
    "variant": "A750P",
    "createDate": "02/15/2015",
    "updateDate": "10/31/2019",
    "referenceTranscriptCoordinates": {
        "id": 135530,
        "transcript": "NM_005228",
        "gDna": "chr7:g.55174785G>C",
        "cDna": "c.2248G>C",
        "protein": "p.A750P",
        "sourceDb": "RefSeq",
        "refGenomeBuild": "GRCh38/hg38"
    },
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 9056,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the addition of Mekinist (trametinib) to WZ4002 treatment did not significantly impact cell viability compared to WZ4002 alone, but delayed onset of drug resistance in a non-small cell lung cancer cell line harboring EGFR A750P and EGFR L747_E749del in culture (PMID: 26036643).",
            "molecularProfile": {
                "id": 26702,
                "profileName": "EGFR L747_E749del EGFR A750P"
            },
            "therapy": {
                "id": 3351,
                "therapyName": "Trametinib + WZ4002",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 6890,
                    "pubMedId": 26036643,
                    "title": "Combined EGFR/MEK Inhibition Prevents the Emergence of Resistance in EGFR-Mutant Lung Cancer.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26036643"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 15496,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, overexpression of PIK3CA E545K in a non-small cell lung cancer cell line harboring EGFR L747_E749del and EGFR A750P resulted in decreased sensitivity to Tagrisso (osimertinib) in culture (PMID: 30228210).",
            "molecularProfile": {
                "id": 31069,
                "profileName": "EGFR L747_E749del EGFR A750P PIK3CA E545K"
            },
            "therapy": {
                "id": 660,
                "therapyName": "Osimertinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "decreased response",
            "references": [
                {
                    "id": 13403,
                    "pubMedId": 30228210,
                    "title": "Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30228210"
                }
            ],
            "ampCapAscoEvidenceLevel": "NA",
            "ampCapAscoInferredTier": "NA"
        },
        {
            "id": 20686,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a retrospective study, BCL2L11 deletion was identified in a non-small cell lung cancer patient harboring EGFR A750P and L747_E749del with primary resistance to icotinib (PMID: 31828849).",
            "molecularProfile": {
                "id": 35281,
                "profileName": "BCL2L11 del EGFR L747_E749del EGFR A750P"
            },
            "therapy": {
                "id": 769,
                "therapyName": "Icotinib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 17988,
                    "pubMedId": 31828849,
                    "title": "Potential mechanism of primary resistance to icotinib in patients with advanced non-small cell lung cancer harboring uncommon mutant epidermal growth factor receptor: A multi-center study.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/31828849"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 2934,
            "profileName": "EGFR A750P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 26702,
            "profileName": "EGFR L747_E749del EGFR A750P",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 31069,
            "profileName": "EGFR L747_E749del EGFR A750P PIK3CA E545K",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 35281,
            "profileName": "BCL2L11 del EGFR L747_E749del EGFR A750P",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        {
            "id": 135530,
            "transcript": "NM_005228",
            "gDna": "chr7:g.55174785G>C",
            "cDna": "c.2248G>C",
            "protein": "p.A750P",
            "sourceDb": "RefSeq",
            "refGenomeBuild": "GRCh38/hg38"
        }
    ]
}